Nicorandil treatment in patients with acute myocardial infarction - A meta-analysis

Circulation Journal

Volumn 73, Issue 5, 2009, Pages 925-931

  Iwakura, Katsuomi ^a   Ito, Hiroshi ^a   Okamura, Atsushi ^a   Koyama, Yasushi ^a   Date, Motoo ^a   Higuchi, Yoshiharu ^a   Inoue, Koichi ^a   Kimura, Ryusuke ^a   Nagai, Hiroyuki ^a   Imai, Michio ^a   Toyoshima, Yuko ^a   Ozawa, Makito ^a   Ito, Norihisa ^a   Okazaki, Yukinori ^a   Shibuya, Masahiko ^a   Suenaga, Hideaki ^a   Kubota, Asuka ^a   Fujii, Kenshi ^a  

^a Sakurabashi Watanabe Hospital   (Japan)

Author keywords

Acute myocardial infarction; Meta analysis; Nicorandil; No reflow

Indexed keywords

CREATINE KINASE; NICORANDIL;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE REPERFUSION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

AGED; CARDIOVASCULAR AGENTS; COMBINED MODALITY THERAPY; CORONARY CIRCULATION; FEMALE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; NICORANDIL; NO-REFLOW PHENOMENON; PUBLICATION BIAS; RECOVERY OF FUNCTION; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 65649142906     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-1059     Document Type: Article

References (46)

1. Kevelaitis E, Oubenaissa A, Peynet J, Mouas C, Menasche P. Preconditioning by mitochondrial ATP-sensitive potassium channel openers: An effective approach for improving the preservation of heart transplants. Circulation 1999; 100: II-345-II-350. (Pubitemid 29523558)
2. Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation 1995; 92: 1236-1245.
3. Yao Z, Gross GJ. Activation of ATP-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. Am J Physiol 1994; 267: H1888-H1894. (Pubitemid 24363736)
4. Matsuda N, Morgan KG, Sellke FW. Preconditioning improves cardioplegia- related coronary microvascular smooth muscle hypercontractility: Role of KATP channels. J Thorac Cardiovasc Surg 1999; 118: 438-445. (Pubitemid 29426644)
5. Ren Z, Yang Q, Floten HS, Furnary AP, Yim AP, He GW. ATP-sensitive potassium channel openers may mimic the effects of hypoxic preconditioning on the coronary artery. Ann Thorac Surg 2001; 71: 642-647. (Pubitemid 32173849)
6. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.
7. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet 2007; 370: 1483-1493. (Pubitemid 47625560)
8. Akagi T, Sarazawa K, Inai Y, Kitagawa M, Takahashi N, Hamanaka I, et al. Continuous administration of nicorandil decreases QT dispersion during the chronic phase of acute myocardial infarction. Int Heart J 2006; 47: 351-361. (Pubitemid 44082830)
9. Fukuzawa S, Ozawa S, Inagaki M, Shimada K, Sugioka J, Tateno K, et al. Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: Assessment with thallium-201/iodine-123 BMIPP dual SPECT. J Nucl Cardiol 2000; 7: 447-453.
10. Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006; 70: 1099-1104. (Pubitemid 44386986)
11. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-773.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
13. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463. (Pubitemid 30422636)
14. Ishii H, Ichimiya S, Kanashiro M, Amano T, Matsubara T, Murohara T. Effects of intravenous nicorandil before reperfusion for acute myocardial infarction in patients with stress hyperglycemia. Diabetes Care 2006; 29: 202-206. (Pubitemid 44106492)
15. Ishii H, Ichimiya S, Kanashiro M, Amano T, Ogawa Y, Mitsuhashi H, et al. Effect of intravenous nicorandil and preexisting angina pectoris on short- and long-term outcomes in patients with a first STsegment elevation acute myocardial infarction. Am J Cardiol 2007; 99: 1203-1207. (Pubitemid 46659858)
16. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med 2007; 48: 1676-1682. (Pubitemid 47572715)
17. Akagi T, Fujimori M, Tabata M, Hama N, Hiraoka Y, Okada I, et al. The effects of nicorandil treatment on QT dispersion (QTd) before and after coronary reperfusion therapy in patients with acute myocardial infarction (AMI). Therapeutic Res 2002; 23: 565-582 (in Japanese).
18. Ueda H, Nakayama Y, Tsumura K, Yoshimaru K, Hayashi T, Yoshikawa J. Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction. Can J Cardiol 2004; 20: 625-629. (Pubitemid 38811581)
19. Hara H, Horinaka S, Yabe A, Yagi H, Tsuboko Y, Yoshida K, et al. Suppressive effect of nicorandil in ventricular arrhythmias after reperfusion therapy in patients with acute myocardial infarction. J Cardiol 2007; 49: 135-141 (in Japanese).
20. Kobayashi Y, Goto Y, Daikoku S, Itoh A, Miyazaki S, Ohshima S, et al. Cardioprotective effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction. Jpn Circ J 1998; 62: 183-189. (Pubitemid 28149910)
21. Kojima S, Matsui K, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, et al. Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. Circ J 2007; 71: 301-307. (Pubitemid 46409529)
22. Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J 2007; 71: 1835-1840. (Pubitemid 350261402)
23. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93: 1993-1999. (Pubitemid 26167228)
24. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-1209.
25. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909-1913. (Pubitemid 34437617)
26. Lepper W, Hoffmann R, Kamp O, Franke A, de Cock CC, Kuhl HP, et al. Assessment of myocardial reperfusion by intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. Circulation 2000; 101: 2368-2374. (Pubitemid 30329126)
27. Porter TR, Li S, Oster R, Deligonul U. The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction. Am J Cardiol 1998; 82: 1173-1177. (Pubitemid 28541270)
28. Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109: 1121-1126. (Pubitemid 38332616)
29. Lim SY, Bae EH, Jeong MH, Kang DG, Lee YS, Kim KH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 2004; 68: 928-932. (Pubitemid 39419487)
30. Ikeda N, Yasu T, Kubo N, Hashimoto S, Tsuruya Y, Fujii M, et al. Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart 2004; 90: 181-185. (Pubitemid 38147154)
31. Lund GK, Stork A, Saeed M, Bansmann MP, Gerken JH, Muller V, et al. Acute myocardial infarction: Evaluation with first-pass enhancement and delayed enhancement MR imaging compared with 201Tl SPECT imaging. Radiology 2004; 232: 49-57. (Pubitemid 38787819)
32. Nagao M, Higashino H, Matsuoka H, Kawakami H, Mochizuki T, Murase K, et al. Clinical importance of microvascular obstruction on contrast-enhanced MRI in reperfused acute myocardial infarction. Circ J 2008; 72: 200-204.
33. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 2001; 88: 802-809. (Pubitemid 32429976)
34. Murata M, Akao M, O'Rourke B, Marban E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: Possible mechanism of cardioprotection. Circ Res 2001; 89: 891-898. (Pubitemid 34627894)
35. Akao M, Teshima Y, Marban E. Antiapoptotic effect of nicorandil mediated by mitochondrial atp-sensitive potassium channels in cultured cardiac myocytes. J Am Coll Cardiol 2002; 40: 803-810.
36. Nicolosi GL, Latini R, Marino P, Maggioni AP, Barlera S, Franzosi MG, et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 1996; 17: 1646-1656. (Pubitemid 26381822)
37. Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-1275.
38. Sugimoto K, Ito H, Iwakura K, Ikushima M, Kato A, Kimura R, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67: 295-300. (Pubitemid 36417595)
39. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-1288. (Pubitemid 41266722)
40. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-2159. (Pubitemid 30253043)
41. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-1780. (Pubitemid 40779856)
42. Toyama T, Seki R, Hoshizaki H, Kawaguchi R, Isobe N, Adachi H, et al. Nicorandil administration shows cardioprotective effects in patients with poor TIMI and collateral flow as well as good flow after AMI. Ann Nucl Med 2006; 20: 277-285. (Pubitemid 44033268)
43. Nameki M, Ishibashi I, Miyazaki Y, Sakai Y, Namikawa S, Kuriyama N, et al. Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction. Circ J 2004; 68: 192-197. (Pubitemid 38405008)
44. Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004; 148: E15. (Pubitemid 39349370)
45. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction. Eur J Nucl Med Mol Imaging 2005; 32: 322-328. (Pubitemid 40562124)
46. Fujiwara T, Matsunaga T, Kameda K, Abe N, Ono H, Higuma T, et al. Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels 2007; 22: 303-309. (Pubitemid 47456660)